cyrilzakka/clinical-trials huggingface dataset:
The Role of 18F-FDG&amp;68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

This study aims to investigate the value of 18F-FDG\&amp;68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

If the target population of the study agrees to participate in the study, we will number the participants, resume their pathology files, and collect their gender, age, phone number, height and weight information, record the participants\&#39; consultation process and the results of the tests and examinations therein. During the course of the study we will perform 18F-FDG \&amp; 68Ga-FAPI PET/CT according to the participant\&#39;s stage of disease, specifically: one 18F-FDG PET/CT prior to conversion therapy and one 68Ga-FAPI PET/CT as a baseline assessment. One 18F-FDG PET/CT and one 68Ga-FAPI PET/CT were performed before the clinician assessed that the conversion therapy was ready to be completed and the conversion surgery was about to be performed, and if the participant experienced a postoperative recurrence of the disease during the study period, another 18F-FDG PET/CT and a 68Ga-FAPI PET/CT would be performed, meaning that a total of 4 PET/CTs were performed. In other words, a total of 4 PET/CT visualizations were required for all participants; 2 additional PET/CT visualizations, including 18F-FDG PET/CT and 68Ga-FAPI PET/CT, were performed if the disease recurred after the conversion surgery, and none were required for participants without recurrence.

Eligibility Criteria:
Inclusion Criteria:

1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
3. Patients voluntarily enrolled in this study by signing an informed consent form
4. Age ≥ 18 years
5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
6. Expected life expectancy ≥ 3 months
7. Adequate organ and bone marrow function
8. Willingness to adhere to the study protocol and follow-up programme

Exclusion Criteria:

1. Signs of distant metastases other than peritoneal metastases at enrolment
2. Pregnant or breastfeeding women.
3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
Skin Tone Measurement Method Investigation for Pulse Oximetry

The primary objective is to gather missing information in order to form a well-founded recommendation on which is the preferred skin pigmentation measurement (PPM) methods in the context of pulse-oximetry.

Skin tone bias in pulse-oximetry (SpO2) needs to be addressed urgently. While skin pigmentation is a prime candidate for the root cause of skin tone bias in SpO2, more research is needed. F A solid comparison and recommendation requires evaluation of several additional aspects that affect accuracy, precision, and reproducibility of the PMMs.

Briefly, these additional aspects that are evaluated in this study are listed below:

* operator bias
* impact of operator color blindness
* probe pressure
* probe aperture size
* device stability
* impact of blood on pigmentation measurement
* feasibility of skin tone measurement on sides of fingers
* intra-operator variability

PMMs included in this study are:

Subjective color matching methods by using:

1. Von Luschan color scale
2. Fitzpatrick color scale
3. Pantone color scale

Objective probe-based measurements by using:

1. Konica Minolta CM700d (reflectance spectrometer)
2. Mx18 (erythema-melanin meter)
3. SPA99 (erythema-melanin meter)

Measurements will be performed on 5 relatively light skinned, and 5 relatively dark skinned volunteers (N=10 in total\*). The study will be executed on the High-Tech Campus Eindhoven (Netherlands) and each participant will have 3 visits of approximately 1.5 to 2 hours/visit.

Eligibility Criteria:
Inclusion Criteria:

1. Adults (18-65 years)
2. Fluent in either English or Dutch
3. Participants who are willing and able to provide informed consent themselves.
4. People with Von Luschan scores \<18 ('light skin' group) or \> 25 ('dark skin' group).

Exclusion Criteria:

1. Skin conditions that could potentially interfere with the measurements:

   * piercings/ink/henna tattoos that cover the left forearm, hands, fingers or forehead
   * vascular or pigmentary or renal psoriasis
   * epidermal bullosum
   * other diseases that affect the skin (tone) of the body
2. COVID-19 exclusion criteria\*:

   * Currently displaying COVID-19-related symptoms, namely a fever, cough and/or difficulty breathing
   * Having been positively tested as infected with COVID-19 in the past 14 days
   * Travelled to or from high risk COVID-19 areas in the past 14 days
   * Been in contact with a (suspected) COVID-infected person in the past 14 days
3. Not being able to travel to Eindhoven 3 times, and/or not being able to comply with the study procedures
4. Sunbathing during the study duration or substantial sun exposure (due to holidays for example).
5. Known allergic reaction to facial make-up
6. Usage of tanning sprays/cremes
7. Wearing make-up during the study visits (mascara is allowed)

   * No testing will be performed in the study. Participants will be asked if they have been positively tested.
Wet Cupping (AlHijamah); Double Versus Single Cupping Technique

Randomized clinical trial to compare the effectiveness and safety of double (traditional) versus single (Asian) cupping techniques in chronic low back pain.

Chronic Low Back Pain is a very common pain disorder in the primary care. As in many chronic pain conditions, patients are usually asking for alternative options, especially local traditional and therapies including wet cupping, to replace the long-term use of painkillers. The majority of the wet cupping trials conducted abroad used different techniques, which is different from our local traditional wet cupping technique. This study can identify the technique that is more efficacious in reducing pain, prolonging the pain relieve period, and decrease patient dependence on painkillers in chronic low back pain.The aim of this study is to compare the effectiveness and safety of double (traditional) versus single (Asian) cupping techniques in chronic low back pain. This a randomized comparative effectiveness pilot clinical trial. After taking written informed consent, patient with chronic low back pain will be randomized into two groups, one group to receive wet cupping therapy with the Traditional double technique, the other group to receive it with the Asian single technique. Numeric Rating Scale, Present Pain Intensity and Oswestry Disability Questionnaire will be used to measure the outcome before and after the intervention, one week after the intervention, then two weeks after. Wilcoxon rank sum test for the continuous dependent data analysis and the analysis of covariance ANCOVA, to compare both groups mean scores will be used. The outcome baseline for each score will be used as the covariate. Chi square or Fisher's exact test will be used to compare categorical data with Minimal Clinical Improvement Difference within and between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Male and Female
* Age equal or more than 18 years up to 60 years
* Chronic low back pain (at least the duration ≥ 3 months)
* Not on anti-inflammatory or pain killers for the last 15 days.

Exclusion Criteria:

* Patients received wet-cupping therapy before in the last three months
* Patients who have low back pain due to specific and known etiological causes (infection, tumor, osteoporosis, ankylosing spondylitis, fracture, inflammatory process, radicular syndrome, and cauda equinal syndrome)
* Patients who are inappropriate to the wet cupping treatment (AIDS, Hepatitis, Tuberculosis, Syphilis. The referring physicians will be advised to exclude those patients)
* Patients currently receiving any anticoagulant, antiplatelet medications
* Anemia, thrombocytopenia, Coagulopathy or Hemorrhagic disease like hemophilia
* Had undergone a surgery, or had bleeding injury, or had blood donation
* Uncontrolled hypertension, Ischemic heart disease, previous transient ischemic attack or stroke
* Diabetes, known renal and / or hepatic diseases
* Patients who are in pregnancy or have plan to conception
* Previously or currently drug addicts
* Any other severe disease or disabling medical condition
Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis

The efficacy and safety of anticoagulant treatment is not established for patients with acute symptomatic isolated distal deep vein thrombosis (IDDVT). The latest Antithrombotic Therapy for VTE Disease Guideline suggested using the same anticoagulation as for patients with acute proximal DVT in patients with acute IDDVT. However, a single-center retrospective cohort study found therapeutic anticoagulation was associated with an increase risk of bleeding. Thus, this study aimed to assess the short-term risk of recurrent venous thrombotic events and bleeding events in patients with a first acute symptomatic IDDVT of the leg treated with prophylactic or therapeutic anticoagulant therapy with rivaroxaban.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18-90
* Outpatients with a first, acute (within 2 weeks), symptomatic, objectively confirmed isolated distal DVT
* Compliance to the scheduled follow up plan
* Ability and willing to participate and sign the informed consent.

Exclusion Criteria:

* Any absolute contraindication to anticoagulant treatment
* Pregnancy or breast-feeding
* Systolic pressure \> 180 mmHg or diastolic pressure \> 100 mmHg
* Platelet count \< 100 × 10⁹ /L
* Serum creatinine \> 180 mmol/L or creatinine clearance ≤30 ml/min
* Liver disease associated with coagulopathy and high risk of bleeding
* Clinically suspected or confirmed pulmonary embolism
* Ipsilateral or contralateral proximal DVT
* Any indication for long-term anticoagulation
* Enrolled in another clinical trial simultaneously
* Life expectancy \< 6 months
The Effect of Photobiomodulation Using Low-Level Diode Laser Therapy on Postoperative Pain in Symptomatic Lower Molar Teeth With Irreversible Pulpitis and Apical Periodontitis; a Randomized Controlled Clinical Trial

this study aims to assess the effect of photobiomodulation using low-level diode laser therapy on postoperative pain after single-visit root canal treatment of mandibular molars with symptomatic irreversible pulpitis and apical periodontitis.


Eligibility Criteria:
Inclusion Criteria:

* . Mature multirooted mandibular molar teeth with: i. Pre-operative sharp pain marked on the VAS scale by reading not less than 6. ii. Clinical diagnosis of symptomatic irreversible pulpitis with periapical periodontitis.

iii. Normal periapical radiographic appearance or slight widening in lamina dura. iv. Positive response and pain provoked by percussion.

- Patients who agree to provide written consent and attend for recall appointments.

Exclusion Criteria:

* Patients who used NSAIDs in the 24 hours before treatment.
* Medically compromised patients having significant systemic disorders. (ASA III or IV).
* Patients with two or more adjacent teeth requiring endodontic treatment.
* Pregnant or nursing females. 5. Teeth that have:

  i. Periodontal affection (with pocket depth greater than 5mm, associated with swelling orfistulous tract, or greater than grade I mobility).

ii. No possible restorability. iii. Signs of pulpal necrosis; associated sinus tract or swelling.
The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM

The investigators intends to carry out a randomized, cross-over, prospective study which will last 48 weeks in youth with T1DM followed up by the center. The purpose is to observe the effects of metformin on glycemic control and insulin sensitivity in adolescents with T1DM based on insulin therapy by using 72h CGMS and hyperinsulinemic euglycemic clamps.


Eligibility Criteria:
Inclusion Criteria:

1. Type 1 diabetes mellitus;
2. Age≥12 yr;
3. Tanner sexual maturation rating 2-5;
4. HbA1c levels: 7.5%-10%;
5. MDI or CSII ≥6 months;
6. Insulin dose ≥ 0.8U/kg before the enrollment，and the dosage is stable at least \>1 month（dosage change\<10%）.

Exclusion Criteria:

1. Serious acute and chronic complications associated with diabetes;
2. Repeated and serious hypoglycemia episodes repeatedly;
3. Hepatic function damage (ALT≥2.5 times higher than the upper limit of the normal accepted range);
4. Moderate to advanced renal impairment (calculated according to MDRD equation: eGFR\<60ml/min/1.73m2);
5. Clinically significant heart attacks: myocardial infarction, arrhythmia，II-III°AVB，unstable angina，decompensated HF（NYHA III\~IV;
6. Female patients who have a sex life and are not willing to use contraceptive methods;
7. Pregnancy.
Motor Evoked Potentials With Modified Facilitation Technique

Investigating the change in Test- Retest- reliability in healthy individuals when applying a modified easy to use facilitation technique compared to standard facilitation technique and analyzing sensitivity and specificity in patients with multiple sclerosis regarding detection of pathologic results


Eligibility Criteria:
Inclusion Criteria for healthy individuals:

* Ability to understand the purpose and risks of the study, provide signed and dated informed consent
* Between 18 and 65 year of age
* No neurologic or psychiatric comorbidity requiring continous treatment
* No previous damage of central nervous System

Inclusion Criteria for patients:

* Ability to understand the purpose and risks of the study, provide signed and dated informed consent
* Between 18 and 65 year of age
* patients with inflammatory diseases of the central nervous system (CNS) or multiple sclerosis appointed for routine MEP diagnostic at the Department of Clinical Neurophysiology, University Hospital Basel

Exclusion Criteria:

* Contraindication for measuring of motoric evoked potentials (MEP): metal implants (pacemaker, stents); known epilepsy oder previous epileptic fit
* Known disease of the peripheral nervous system (polyneuropathy)
Outreach and Treatment for Depression in the Labor Force

This study will assess the effects of depression treatment on employee productivity. This study will also evaluate the impact of depression screening and outreach on employees' receptivity to treatment.

This study is conducted in three phases. In the first phase, employees from various companies participate in an on-line Health Risk Assessment survey at a secure website. Those who display symptoms of depression participate in a brief telephone interview to confirm the depression diagnosis.

In the second phase, depressed participants are randomly assigned to receive either intervention treatment or usual care for 18 months. The intervention consists of periodic telephone contact with a mental health clinician who provides education regarding depression and its treatment. Participants receiving the intervention are also provided with resources to obtain psychotherapy and/or pharmacotherapy. Those who do not seek treatment are monitored and supported. Participants in the usual care arm are informed of their possible depression and are encouraged to seek professional treatment.

The final phase of the study involves data analysis and dissemination of aggregated results. Surveys and questionnaires are used to assess participants.

Eligibility Criteria:
Inclusion Criteria:

* Major depressive episode
* Employed
ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO

Vitiligo is characterized by the selective loss of melanocytes, which in turn leads to totally amelanotic, non-scaly, chalky-white macule with distinct margins Vitiligo is the most common depigmenting skin disorder, with an estimated prevalence of 0.5-2% of the population in both adults and children worldwide Tumor necrosis factor (TNF-α), a pro-inflammatory cytokine is necessary for Th1 mediated response and immune homeostasis and the up-regulation of TNF-α can result in chronic inflammatory and autoimmune diseases . previous studies revealed a rise in transcript and protein levels of TNF-α in vitiligo patients The prime location of melanocytes, keratinocytes and fibroblasts is the epidermal microenvironment and these cells are capable of TNF-α expression and secretion TNF-α acts as an autocrine as well as a paracrine manner to suppress the melanocyte growth and proliferation ( Tristetraprolin (TTP) zinc finger protein 36 (ZFP36) is Ribonucleic acid (RNA) binding protein that preferentially binds to Adenylate-uridylate-rich (AU-rich) regions in the 3' untranslated regions (3'UTR) of target genes . Additionally, Tristetraprolin functions by destabilizing mRNAs encoding for oncogenes, cytokines (as TNFα), and chemokines involved in the inflammatory processes, by favoring their degradation and/or preventing their efficient translation The expression of proinflammatory mediator genes is tightly controlled by post-transcriptional regulation, which is mediated by a set of immune-related RNA binding proteins, such as tristetraprolin, Roquin, and Regnase


Eligibility Criteria:
Inclusion Criteria:

* This study will include adult patients\>18 yrs with non -segmental vitiligo attending the dermatology outpatient clinics at Sohag University, Egypt. A group of participants will be included as a control group.This control group will be taken from patients seeking for abdominoplasty in plastic surgery department at Sohag University Hospital.

Exclusion Criteria:

- 1)Pregnancy. 2)Patients with chronic inflammatory skin disorders. 3)Patients on antioxidants or anti-inflammatory drugs. 4)Patients on topical or systemic treatment for vitiligo in the last 4 weeks prior to enrollment in the study.

5)Patients with other autoimmune diseases as thyroiditis. lupus erythematosus and rheumatoid arthritis 6)Patients with diabetes mellitus (DM).
Effect of Simethicone on Bowel Preparation for Colonoscopy

Optimal bowel preparation is essential for colonoscopy efficacy and safety. Mucosal visualization during colonoscopy is often limited by residual stool, bubbles, bile, intraluminal fluid, and debris, which increase the risk of missing flat adenomas or other small lesions.Therefore, intestinal preparation is necessary to remove residual materials prior to endoscopy.

A combined agent, low-dose PEG with ascorbic acid (PEG-Asc), is one low-volume solution commonly used in Korea (Coolprep®; TaeJoon Pharmaceuticals, Seoul, Korea). However, practitioners have noted an increased incidence of bubble formation with this preparation method.

To the investigators knowledge, no previous study has assessed colon preparation in patients administered simethicone.

The purpose of this study was to compare the quality of bowel preparation and compliance between PEG-Asc and PEG-Asc with simethicone. The effectiveness of adding simethicone as an antifoaming agent to improve bowel cleansing for colonoscopy was evaluated in terms of bowel preparation scale and bubble score, and the compliance of both patients and endoscopists was also investigated using a questionnaire.

1. Study design: endoscopist-blinded, prospective, randomized controlled trial
2. Subjects

   - A single-center, randomized, observer-blinded study was performed at Korea University Hospital in Anam. Outpatients were prospectively enrolled. Each group of the patients will receive PEG-Asc or PEG-Asc with simethicone before colonoscopy.
3. Sampling design: Consecutive recruitment of consenting patients
4. Variables Predictor

   1. group 1 (PEG-Asc) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;
   2. group 2 (PEG-Asc with simethicone) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure;Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
5. Primary Outcome: Quality of bowel preparation \[Boston Bowel Preparation Scale, bubble score\]
6. Secondary Outcome: Patients and endoscopists' compliance\[Tolerability, palatability of patient, fatigue score of endoscopist\]

Eligibility Criteria:
Inclusion Criteria:

* Male or female patients,
* aged between18 and 80 years undergoing elective outpatient colonoscopy were eligible for the study

Exclusion Criteria:

* patients who had chronic kidney disease,
* severe heart failure(New York Heart Association \[NYHA\] class III or IV)
* uncontrolled hypertension (systolic pressure ≥170 mm Hg, diastolic pressure ≥100 mm Hg)
* severe constipation
* any bowel resection
* significant gastroparesis, or
* suspected bowel obstruction or perforation.
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany

This is a prospective, non-interventional, multi-center study, in subjects with clinical indication of Human Immunodeficiency Virus (HIV)-1 infection. The aim of the study is to generate the real world evidence for the use of DTG+3TC in routine clinical care in Germany to supplement data obtained from controlled clinical trials. Approximately, 300 treatment naïve and pre-treated HIV-1 positive subjects will be enrolled in the study. The observation period for the study will be 3 years. Data will be collected from routine clinical care via electronic data capture (EDC) system.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with \>= 18 years of age.
* Subjects with documented HIV-1 infection.
* Prescription of DTG + 3TC was issued independently from entering this study.
* Subjects with the ability to understand informed consent form and other relevant regulatory documents.

Exclusion Criteria:

* Any contraindication according to Tivicay or Lamivudine summaries of product characteristics (SmPCs).
* Subjects with VL \> 500 c/mL.
* Any antiretroviral therapy for the treatment of HIV-1 in addition to DTG and 3TC or the DTG/3TC fixed dose combination (FDC).
* Subjects with hepatitis B virus (HBV)- coinfection.
* Subjects with current participation in the ongoing non-interventional study TRIUMPH (study number: 202033, NCT number: NCT02342769) or in any interventional clinical trial irrespective of indication.
* Subjects who had previously participated in clinical trials assessing DTG+ 3TC.
Effect of Hyperoncotic Albumin on Vascular Hemodynamics and Oxygen Delivery Following Orthotopic Liver Transplant

The primary aim of this study is to assess the effect of hyperoncotic albumin on vascular hemodynamics and oxygen delivery after orthotopic liver transplant. The secondary aim is to try to identify the dominant physiological mechanism so that we will be able to better identify patients that may benefit from the use of albumin (25%) boluses in addition to standard care in patients following liver transplantation.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Patients from the Critical care Unit
* Patients with a pulmonary artery occlusion catheter Inclusion:patients immediately following liver transplantation

Exclusion Criteria:

* Patients not giving informed consent
* Patients who have received \> 300 ml of albumin within 24 hours prior to inclusion
* Patients known to have previous adverse reaction to human albumin solution
* Patients who have religious restriction to receive human blood products
* Patient who have initial graft failure
* Patients with fluctuating hemodynamics
* Concerns of the treating surgeon